Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) Equity Average (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Equity Average over the past 15 years, most recently at $1.8 million for Q2 2025.

  • For Q2 2025, Equity Average fell 87.71% year-over-year to $1.8 million; the TTM value through May 2025 reached $1.8 million, down 87.71%, while the annual FY2025 figure was $6.3 million, 78.56% up from the prior year.
  • Equity Average for Q2 2025 was $1.8 million at Lifecore Biomedical, Inc. \De\, down from $8.8 million in the prior quarter.
  • Over five years, Equity Average peaked at $205.1 million in Q1 2021 and troughed at -$8.9 million in Q3 2023.
  • A 5-year average of $72.1 million and a median of $34.2 million in 2023 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: crashed 110.74% in 2023 and later soared 194.82% in 2024.
  • Year by year, Equity Average stood at $174.3 million in 2021, then crashed by 57.25% to $74.5 million in 2022, then tumbled by 108.15% to -$6.1 million in 2023, then soared by 194.82% to $5.8 million in 2024, then tumbled by 69.03% to $1.8 million in 2025.
  • Business Quant data shows Equity Average for LFCR at $1.8 million in Q2 2025, $8.8 million in Q1 2025, and $5.8 million in Q4 2024.